Aprea closes EUR46m Series B financing
Aprea AB, a clinical-stage biotechnology company developing novel anticancer therapies targeting the tumour suppressor protein p53, has completed a Series B financing round, raising EUR46 million (approximately USD 51 million). The international syndicate was co-led by Versant Ventures and 5AM Ventures, with participation by Sectoral Asset Management. HealthCap acted as
